Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.

PAPERS | | |

Source: Cephalalgia 2023 Apr; 43(4). doi: 10.1177/03331024231156922Authors: Giri S, Tronvik E, Linde M, Pedersen SA, Hagen K

This systematic review focuses on chronic migraine patients with medication overuse headache using, respectively, topiramate, botulinum toxin type A, and human monoclonal antibodies targeting calcitonin gene-related peptide or its receptor.

Pubmed ID: https://pubmed.ncbi.nlm.nih.gov/36856015/

Paper chosen by Rebecca Seal

Leave a Comment

You must be logged in to post a comment.

Recent Papers

The analgesic efficacy of opioids in different application modalities for the treatment of breakthrough cancer pain-a systematic review with network meta-analysis

October 16, 2026 | Basic Research,  Clinical Research

Emotional imagery alters symptom perception but not postural or respiratory behavior in individuals with chronic non-specific low back pain

October 16, 2026 | Clinical Research

Headache disorders among Indigenous communities: A scoping review undertaken with knowledge keeper guidance

October 16, 2026 | Clinical Research

Plasma amylin levels in migraine and after erenumab treatment: A REFORM study

October 16, 2026 | Clinical Research

The MIND study: Design, feasibility, and baseline characteristics of a smartphone-based migraine cohort

October 16, 2026 | Clinical Research